Hansoh Pharmaceutical (03692) Announces HS-20152 Injection Receives NMPA Approval for Clinical Trials

Hansoh Pharma (03692) announced that HS-20152 Injection, a self-developed Class 1 new drug by the Group, has received clinical trial approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of paroxysmal nocturnal hemoglobinuria.